|Articles|December 1, 2006

Cunningham joins MacuSight board of directors

Union City, CA-MacuSight Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, announced the appointment of Brian C. Cunningham to its board of directors.

Union City, CA-MacuSight Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, announced the appointment of Brian C. Cunningham to its board of directors.

Cunningham presently serves as chief executive officer of DaoGen Inc. and Clerigen Inc., both early stage biopharmaceutical companies, and is of counsel to Cooley Godward Kronish LLP in its business department. In addition, Cunningham is a director of Synarc Inc., a private, imaging-based clinical research organization.

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Cunningham joins MacuSight board of directors

Related Content

How to better understand ophthalmic drug shortage impacts, with Ian Pitha, MD, PhD

Ophthalmic drug shortages are 'eroding' patient trust, with Ian Pitha, MD, PhD

Aerie Pharmaceuticals CEO discusses what's new in the pipeline

ImprimisRx offers a look at three new products in the pipeline

Making the grade: FDA approves first biosimilar product for retinal diseases

Latest CME

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Retina Updates in Montréal

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

FDA guidance to help accelerate cell and gene therapies

Closing the gap: John Berdahl, MD, on the global cataract burden and the emerging dementia connection

Everest Medicines acquires Greater China rights to Aceclidine Presbyopia Eye Drop (VIZZ)

Treatment Goals in Retinal Vascular Diseases

The Residency Report: Cardiovascular risk scores as a window into ocular disease